Cargando…

Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach

Accurate determination of relapses in multiple sclerosis is important for diagnosis, classification of clinical course and therapeutic decision making. The identification of biofluid markers for multiple sclerosis relapses would add to our current diagnostic armamentarium and increase our understand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeo, Tianrong, Probert, Fay, Sealey, Megan, Saldana, Luisa, Geraldes, Ruth, Höckner, Sebastian, Schiffer, Eric, Claridge, Timothy D W, Leppert, David, DeLuca, Gabriele, Kuhle, Jens, Palace, Jacqueline, Anthony, Daniel C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568847/ https://www.ncbi.nlm.nih.gov/pubmed/34755110 http://dx.doi.org/10.1093/braincomms/fcab240

Ejemplares similares

A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application
por: Yeo, Tianrong, et al.
Publicado: (2020)

Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
por: Probert, Fay, et al.
Publicado: (2021)

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
por: Yeo, Tianrong, et al.
Publicado: (2022)

Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands
por: Probert, Fay, et al.
Publicado: (2022)

Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
por: Probert, Fay, et al.
Publicado: (2022)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
por: Yeo, Tianrong, et al.
Publicado: (2019)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
por: Jurynczyk, Maciej, et al.
Publicado: (2017)

Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
por: Larkin, James R., et al.
Publicado: (2022)

Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis
por: Probert, Fay, et al.
Publicado: (2018)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
por: Yeo, Tianrong, et al.
Publicado: (2020)

Metabolomics Biomarkers of Prostate Cancer: A Systematic Review
por: Kdadra, Marouane, et al.
Publicado: (2019)

The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis
por: Lennox, Belinda, et al.
Publicado: (2022)

Erratum to: Objective Biomarkers for Clinical Relapse in Multiple Sclerosis: A Metabolomics Approach
Publicado: (2021)

Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis
por: Juryńczyk, Maciej, et al.
Publicado: (2021)

Double-negative neuromyelitis optica spectrum disorder
por: Wu, Yan, et al.
Publicado: (2023)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease
por: Geraldes, Ruth, et al.
Publicado: (2020)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

The influence of HLA‐DRB1*15 on the relationship between microglia and neurons in multiple sclerosis normal appearing cortical grey matter
por: Yates, Richard L., et al.
Publicado: (2021)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis
por: Gray, Elizabeth, et al.
Publicado: (2015)

Shared imaging markers of fatigue across multiple sclerosis, aquaporin-4 antibody neuromyelitis optica spectrum disorder and MOG antibody disease
por: Camera, Valentina, et al.
Publicado: (2023)

Modifying the maternal microbiota alters the gut–brain metabolome and prevents emotional dysfunction in the adult offspring of obese dams
por: Radford-Smith, Daniel E., et al.
Publicado: (2022)

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
por: Bar-Or, Amit, et al.
Publicado: (2023)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis
por: Cagol, Alessandro, et al.
Publicado: (2022)

A protocol for a randomised double-blind placebo-controlled feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS)
por: Coe, S., et al.
Publicado: (2018)

Serum Myo-Inositol, Dimethyl Sulfone, and Valine in Combination with Creatinine Allow Accurate Assessment of Renal Insufficiency—A Proof of Concept
por: Ehrich, Jochen, et al.
Publicado: (2021)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target
por: Zahoor, Insha, et al.
Publicado: (2022)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

‘Hummingbird’ Sign in a Patient with Guam Parkinsonism-Dementia Complex
por: Yeo, Tianrong, et al.
Publicado: (2017)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration
por: Torres, Julia Baguña, et al.
Publicado: (2022)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology
por: Kolasinski, James, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7s9san1u3ait13e3idf499oc1u